Search the Newsreel

Ellomay Capital Ltd (ELLO) Q3 2024 Earnings: Positive EPS Reported Amid Market Decline - Margin Compression Risk

Bausch Health stock gains after Q2 2026 beat (BHC:NYSE)

Bausch + Lomb (BLCO) Stock Rallies On Margin Gains As Losses Narrow

Loma Negra Compania Industrial Argentina (LOMA) Projected to Post Earnings on Thursday

Premium IOLs Help Propel Strong Q2 as Bausch + Lomb Reports Growth and Raises 2026 Guidance

Bausch + Lomb (NYSE/TSX: BLCO) reported strong second-quarter 2026 financial results, with total revenue increasing by 9 percent to $1.394 billion, driven by double-digit growth in surgical and pharmaceuticals. The company also raised its full-year 2026 revenue guidance. This growth was significantly propelled by …

Bausch & Lomb Earnings: Momentum in Implantables and Pharmaceuticals Shows Off Investment Dividends

Bausch & Lomb reported $1.4 billion in revenue, exceeding FactSet consensus by 2% and showing 9% year-over-year growth, though adjusted EPS of $0.17 was 3% below consensus. Despite the mixed earnings, shares remained flat. The report highlights strong first-half performance, indicating that the company's …

Bausch + Lomb Upgrades Full-Year Outlook on Strong Second Quarter

Bausch + Lomb has upgraded its full-year outlook following a strong second quarter performance. This positive revision indicates the company's robust financial health and optimistic projections for the remainder of the year.

Bausch & Lomb Corp 2026: Revenue $1.39B, EPS ($0.04) — 10-Q Summary

Bausch & Lomb Corp (BLCO) reported strong second-quarter 2026 results with revenue reaching $1.39 billion, an increase driven by pricing and volume gains across segments. The company significantly reduced its net loss compared to the prior year, with diluted loss per share narrowing to …

Bausch & Lomb Corp (BLCO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Bausch & Lomb Corp (NYSE:BLCO) reported 8% constant currency revenue growth, showcasing consistent performance across …

Bausch + Lomb Corporation Raises Earnings Guidance for the Full Fiscal Year 2026

Bausch + Lomb Corporation has updated its earnings guidance for the full fiscal year 2026, raising its revenue expectations. The company now anticipates revenue to fall between $5.440 billion and $5.540 billion, an increase from its previous forecast of $5.420 billion to $5.520 billion.

Bausch + Lomb (BLCO) Q2 Earnings Meet Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.16 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was …

Earnings Flash (BLCO) Bausch + Lomb Corporation Posts Q2 Adjusted EPS $0.15 per Share, Vs. FactSet Est of $0.15

Bausch + Lomb Corporation (BLCO) announced its Q2 adjusted earnings per share (EPS) of $0.15, meeting FactSet's estimate. This financial report provides key insights into the company's performance for the second quarter.

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

Revenue of $1.394 Billion Revenue Grew 9% as Reported and 8% on a Constant Currency1 Basis Compared to the Second Quarter of 2025 GAAP Net Loss Attributable to Bausch + Lomb Corporation of $14 Million Adjusted EBITDA (non-GAAP)1 of $241 Million; Adjusted EBITDA Excluding …

Empowered Funds LLC Buys New Holdings in Palomar Holdings, Inc. $PLMR

Empowered Funds LLC has acquired a new position in Palomar Holdings, Inc. (NASDAQ:PLMR) during the first quarter, purchasing 195,118 shares valued at approximately $23.32 million. This acquisition makes Empowered Funds LLC a 0.74% owner of Palomar. Other institutional investors have also adjusted their holdings …

Bausch + Lomb (NYSE: BLCO) lifts revenue but remains loss-making

Is Bausch + Lomb (BLCO) Undervalued As EyeGility Launch And Earnings Draw Focus?

Bausch + Lomb Corporation 2026 Q2 - Results - Earnings Call Presentation (NYSE:BLCO) 2026-07-29

Bausch + Lomb (BLCO) reported strong Q2 2026 results, with an 8% constant currency revenue growth and a 28% increase in adjusted EBITDA, leading to a 17.6% adjusted EBITDA margin. The company raised its full-year revenue and adjusted EBITDA guidance, driven by consistent performance …

Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations

Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations Eyecare company Bausch + Lomb (NYSE:BLCO) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 9.1% year on year to $1.39 billion. The company expects the full year's revenue to be around …

Bausch + Lomb: Q2 Earnings Snapshot

Bausch + Lomb Corporation reported a Q2 loss of $14 million, or 4 cents per share, which adjusted to 16 cents per share, meeting Wall Street expectations. The company recorded revenue of $1.39 billion, exceeding analyst forecasts, and anticipates full-year revenue between $5.42 billion …

Bausch + Lomb Corp (BLCO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Bausch + Lomb Corp (BLCO), rating its current risk score at 7.06, placing it 43rd out of 199 in the Healthcare Equipment & Supplies industry. Key metrics include a beta of 0.58, indicating lower volatility compared to …

Palomar Holdings, Inc. Announces Second Quarter 2026 Financial Results Release Date and Conference Call

Palomar Holdings, Inc. (NASDAQ: PLMR) is scheduled to release its second-quarter 2026 financial results on Tuesday, August 6, 2026. The company will also host a conference call and webcast to discuss these results, providing investors and analysts an opportunity to review their performance and …

Palomar Holdings Q2 Results: Earnings Release Date Set for August 4

Palomar Holdings, Inc. announced that it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after market close. A conference call for investors and analysts is scheduled for Wednesday, August 5, 2026, at 12:00 p.m. Eastern Time to discuss the …

Form 144 Palomar Holdings For: 28 July By Investing.com

This article briefly reports on a Form 144 filing for Palomar Holdings (PLMR) on July 28. It is a very short news piece, providing only the title and the company ticker with a slight positive movement, indicating a routine disclosure of intent to sell …

Planned PLMR (NASDAQ: PLMR) insider stock sale disclosed in Form 144

A Form 144 filing indicates a planned sale of Palomar Holdings, Inc. (PLMR) common stock by an insider through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing details proposed sales of 1,077 and 1,991 restricted common shares, originally received as compensation, with …

Palomar schedules Q2 results Aug. 4, call follows Aug. 5

Palomar Holdings, Inc. (NASDAQ: PLMR) announced it will release its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. The company will then host an earnings conference call on Wednesday, August 5, 2026, at 12:00 p.m. Eastern Time. Investors can …

Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ: TELO) Stock Price, News & Analysis

This article provides a detailed financial overview and news analysis for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), including its current stock price, key financials, income statements, balance sheets, cash flow, and peer comparison. It also offers a company profile highlighting its focus on developing therapeutic …

TELO|Telomir Pharmaceuticals Inc|Price:1.210|Chg%:-0.040

Telomir Pharmaceuticals Inc. (TELO) is a preclinical-stage pharmaceutical company focused on developing Telomir-1, a novel small molecule designed to lengthen protective telomere caps to combat age-related conditions such as Progeria, Wilson's disease, and Alzheimer's. The company aims to commercialize Telomir-1, an orally dosed drug, …

Telomir Pharmaceuticals Inc (TELO) Income Statement

This article presents the quarterly and annual income statements for Telomir Pharmaceuticals Inc (TELO), detailing financial performance metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income. The data spans from FY2022Q1 to FY2026Q1, highlighting the company's consistent losses across …

Palomar (NASDAQ:PLMR) President Jon Christianson Sells 3,000 Shares of Stock

Palomar's President, Jon Christianson, recently sold 3,000 shares of the company's stock for a total of $418,500, reducing his overall holdings by 4.32%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. The company's stock has been performing well, trading near its …

Palomar (NASDAQ:PLMR) CEO Mac Armstrong Sells 3,500 Shares of Stock

Palomar CEO Mac Armstrong sold 3,500 shares of PLMR stock for $480,410, retaining 325,888 shares valued at $44.7 million. This sale was conducted under a pre-arranged Rule 10b5-1 plan. The company's shares recently rose by 3.6% to $145.92, nearing its one-year high, following a …

Will Palomar (PLMR) Beat Estimates Again in Its Next Earnings Report?

Palomar (PLMR) is in a strong position to beat its next earnings estimates, continuing a trend from its previous two reports. The company has a positive Zacks Earnings ESP of +3.77% and a Zacks Rank #3 (Hold), indicating a high probability of exceeding consensus …

Bausch + Lomb Launches the EyeGility Inserter Preloaded IOL Delivery System

Bausch + Lomb has launched its new EyeGility Inserter preloaded IOL delivery system in the U.S. This system is designed for use with enVista Aspire and Envy IOLs, offering convenient one-handed operation and smooth delivery with a silicon soft-tipped plunger. The EyeGility Inserter aims …

Palomar: What I Will Be Looking Out For In Q2 Results

PLMR|Palomar Holdings Inc|Price:140.770|Chg%:+3.210

This article provides a detailed company profile for Palomar Holdings Inc (PLMR), an insurance holding company specializing in property and casualty products. It covers their business scope across five product categories, financial data including market performance, and executive leadership. Key information such as top …

Bausch + Lomb Corporation Revenue Breakdown – MUN:S2L

Bausch + Lomb Corporation (MUN:S2L) generated €4.34 billion in revenue last year, with its Vision Care segment contributing the most at €2.49 billion. Geographically, the United States and Puerto Rico was the largest source of revenue, accounting for €2.17 billion. This data provides a …

Telomir Pharmaceuticals (TELO) awards director 50,000 options at $1.34 exercise price

Telomir Pharmaceuticals (TELO) has granted director Edward Clouston MacPherson 50,000 non-qualified stock options at an exercise price of $1.34 per share. The options, which vested immediately, were issued on April 16, 2026, under the company's 2023 Omnibus Incentive Plan and expire on April 16, …